中
About
Our Mission & Vision
Team
Leadership
Board of Directors
Milestones
Pipeline
Ophthalmology
Business Development
Business Development
Newsroom
Press Releases
In The News
Media Room
Careers
Value & Behaviors
Benefits
Open Positions
Contact
About
Our Mission & Vision
Team
Milestones
Pipeline
Ophthalmology
Business Development
Business Development
Newsroom
Press Releases
In The News
Media Room
Careers
Value & Behaviors
Benefits
Open Positions
Contact
中
Bridging the gap between unmet patient needs and
Read More
From science to medicine, we commit to bring
Read More
LATEST NEWS
February 19, 2024
AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA
®
for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis
LATEST NEWS
October 31, 2023
AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA
®
in Patients after Cataract Surgery
LATEST NEWS
October 10, 2023
AffaMed Technologies Announces Licensing of EVOLUX
®
- a novel extended monofocal intraocular lens (IOL) designed to provide better intermediate vision and equivalent distance vision when compared to a standard monofocal IOL
LATEST NEWS
September 25, 2023
AffaMed Therapeutics Announces Clinical Trial Application Approval in Mainland China for Risuteganib (Luminate
®
) First-in-Class Candidate for the Treatment of Intermediate Dry AMD
Our Areas of Focus
We are advancing a strong group of innovative clinical assets in ophthalmology. These drug candidates provide us a risk-balanced portfolio in a mix of major disease states characterized by high unmet patient needs.
Ophthalmology
Who We Are
AffaMed Therapeutics is a late clinical-stage biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs in ophthalmology. We hope to bring the benefit of our products to patients in Greater China and around the world.
Read More
Strong Leadership Team of Seasoned Executives
Extensive Global Network
Deep Insights into Ophthalmology
Newsroom
February 19, 2024
AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA
®
for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis
Read More
October 31, 2023
AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA
®
in Patients after Cataract Surgery
October 10, 2023
AffaMed Technologies Announces Licensing of EVOLUX
®
- a novel extended monofocal intraocular lens (IOL) designed to provide better intermediate vision and equivalent distance vision when compared to a standard monofocal IOL
September 25, 2023
AffaMed Therapeutics Announces Clinical Trial Application Approval in Mainland China for Risuteganib (Luminate
®
) First-in-Class Candidate for the Treatment of Intermediate Dry AMD
-306.jpg)
-557.jpg)
